Although pharmacy benefit managers say they are supportive of efforts to increase the availability and use of biosimilar alternatives to common high-cost prescription drugs, the Association for Accessible Medicines’ (AAM) Biosimilars Council released a new analysis showing that health plans and patients have missed out on up to $6 billion in savings related to biosimilars for the blockbuster drug Humira due to rebate schemes by PBMs. The analysis, conducted by IQVIA, notes that while smaller PBMs not aligned with the...